TET2 and hematopoietic and lymphoid cell neoplasm: The prognosis of TET2 mutations in haematological tumours is controversial; some articles have reported that it has a prior prognosis in MDS patients or has no significant impact [17, 41], while others have reported that it has no significant influence or an adverse impact in AML patients with normal karyotypes [42, 43].